Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma
Open Access
- 5 December 2018
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 10 (2) , 170-174
Abstract
Background: The aim of this study was to investigate the relationship between EGFR mutation and computed tomography (CT) features in patients with adenocarcinoma of the lung.Methods: One hundred and ninety two lung adenocarcinoma patients who underwent surgery were retrospectively included in this study. Examination of EGFR gene mutation was performed on all resected tumor samples. The 192 recruited lung adenocarcinoma patients were divided into groups according to EGFR mutation status: patients with mutations in exons 18–21 (effective mutated, n = 61) and non‐mutated (n = 131). The clinical characteristics and lung CT imaging features of the two groups were recorded and compared. Univariate and logistic regression analysis were performed to identify the independent risk factors relevant to effective EGFR gene mutation.Results: The independent risk factors relevant to effective EGFR mutation were evaluated by logistic regression test. The results indicated that female gender (odds ratio [OR] 3.23), lung CT features of lymphangitis carcinomatosa (OR 2.66), semi‐solid lesion density (OR 3.56), and spicule sign (OR 1.61) were independent risk factors relevant to EGFR mutation.Conclusion: Female patients with lung CT features of lymphangitis carcinomatosa, semi‐solid lesion density, and spicule sign are more prone to harbor EGFR gene mutations and are more likely to benefit from targeted therapy.Keywords
This publication has 23 references indexed in Scilit:
- Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristicsEuropean Radiology, 2016
- Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion2015
- Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFRBMC Cancer, 2015
- Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialThe Lancet Oncology, 2015
- CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung CancerEuropean Radiology, 2015
- Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatmentLung Cancer, 2014
- Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancerLung Cancer, 2012
- Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR GeneClinical Cancer Research, 2011
- Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?Nature Clinical Practice Oncology, 2007